mRNA vaccines and therapies have had a profound effect on the way various diseases, including infectious diseases like Covid-19, are treated. Scientists are working to improve how these treatments can be leveraged even more, and a research team has made a discovery that could introduce an improved mRNA platform through which vaccines and other treatments for cancer, infectious diseases and autoimmune conditions can be delivered more efficiently using lower doses than has been the norm.
This new study was conducted by a joint team of scientists from Johns Hopkins Medicine, the National Cancer Institute, and Leidos Biomedical Research. The National Institutes of Health (NIH) funded the research.
For their study, the team compared the standard mRNA platform called m1Ѱ (N1-Methylpseudouridine) that was and is being used to develop various vaccines and treatments, against a new platform called ac4C (N4-acetylcytidine). The purpose of the investigation was to find out which platform had the potential to deliver more modified therapeutic proteins at a faster rate.
Their analysis showed that ac4C resulted in a larger payload of therapeutic proteins that could combat disease unlike the standard platform that delivered fewer therapeutic proteins. The team noticed that in the standard platform, proteins moved slower because a jam was created as they transited through the body’s immune cells.
Biophysical chemistry and biophysics professor Bin Wu, who participated in the research, explains that their study looked at some RNA modifications that hadn’t previously been studied for therapeutic purposes. He adds that about 170 RNA modifications exist, but only a few have been investigated.
Leveraging the new mRNA platform that they found to yield better outcomes than the standard one, could make it possible to develop better therapeutics for different diseases, such as infectious diseases, cancer or even autoimmune conditions.
The existing mRNA platform exploits the ability of ribosomes to travel through a single strand of mRNA in the body. However, that single-file movement creates a jam and results in fewer medicinal proteins being created. By using the new platform, more ribosomes can get through quickly and trigger a stronger therapeutic effect.
In future, the new platform can help in creating mRNA-based vaccines and treatments that are stronger and require smaller doses, potentially reducing side effects like the cytokine storms that wreaked havoc in Covid-19 patients.
As superior therapeutic development platforms are developed, concurrent advancements in the diagnostics field, such as those being made by enterprises like Co-Diagnostics Inc. (NASDAQ: CODX) could see diagnosis being done faster and treatment of infectious diseases, cancers, and autoimmune ailments also being undertaken swiftly to reduce the toll of these conditions.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for…
Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed…
A recent study has found that patients diagnosed with glioblastoma, a deadly brain cancer, can…
A new study whose results are yet to be peer-reviewed has shown that a personalized mRNA…
The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare…
Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the…